Indication
Bladder Cancer, Stage I AJCC v8
5 clinical trials
4 products
2 drugs
Clinical trial
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder CancerStatus: Recruiting, Estimated PCD: 2025-03-31
Drug
GemcitabineProduct
PembrolizumabClinical trial
A Phase I Microtrial With PLZ4-Coated Paclitaxel-Loaded Micelles (PPM) in Patients With Recurrent or Refractory Non-Myoinvasive Bladder CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Acupuncture vs. Standard of Care for Induction Intravesical BCG-Related Adverse Events in High-Risk Non-Muscle Invasive Bladder CancerStatus: Completed, Estimated PCD: 2022-08-16
Product
BCGClinical trial
A Window of Opportunity Phase II Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical CystectomyStatus: Completed, Estimated PCD: 2023-05-01
Drug
mFOLFOX6Clinical trial
Pilot Study of an IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerStatus: Recruiting, Estimated PCD: 2026-06-01
Product
PD-L1/IDO Peptide Vaccine